

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 25, 2014

DELMAR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada

000-54801

99-0360497

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)

Suite 720-999 West Broadway
Vancouver, British Columbia
Canada V5Z 1K5
(Address of principal executive offices)

(604) 629-5989
(Registrant's telephone number, including area code)

Copies to:
Gregory Sichenzia, Esq.
Jeff Cahlon, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway
New York, New York 10006
Phone: (212) 930-9700
Fax: (212) 930-9725

(Former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events.

On November 25, 2014, DelMar Pharmaceuticals, Inc. (the "Company") submitted to OTC Markets Group, in connection with the Company's application to have its common stock quoted on the OTCQX, certain pro forma unaudited financial information, a copy of which is attached as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Pro forma financial information

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DELMAR PHARMACEUTICALS, INC.

Dated: November 25, 2014

By: /s/ Jeffrey Bacha
Name: Jeffrey Bacha
Title: Chief Executive Officer

DelMar Pharmaceuticals, Inc.

October 31, 2014 Pro Forma Balance Sheet
(Unaudited)

Pro Forma Adjustments

	September 30, 2014 Balances	1	2	3	4	5	October 31, 2014 Pro Forma Balances
Assets							
Current Assets							
Cash and cash equivalents	4,315,746	738,626		-360,000			4,694,372
Taxes and other receivables	19,340						19,340
Prepaid expenses	162,246						162,246
	<u>4,497,332</u>	<u>738,626</u>	<u>0</u>	<u>-360,000</u>	<u>0</u>	<u>0</u>	<u>4,875,958</u>
Liabilities							
Current liabilities							
Accounts payable and accrued liabilities	293,989						293,989
Related party payables	41,674						41,674
	<u>335,663</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>335,663</u>
Stock option liability	182,065						182,065
Derivative liability	3,458,662	-346,018	-825,502		916		2,288,058
	<u>3,976,390</u>	<u>-346,018</u>	<u>-825,502</u>	<u>0</u>	<u>916</u>	<u>0</u>	<u>2,805,786</u>
Stockholder's equity							
Preferred stock	278,530						278,530
Common stock	36,842	1,136				187	38,165
Additional paid-in capital	13,982,362	1,083,508	825,502			206,299	16,097,671
Warrants	6,187,805						6,187,805
Accumulated deficit	-19,985,775			-360,000	-916	-206,486	20,553,177
Accumulated other comprehensive income	21,178						21,178
	<u>520,942</u>	<u>1,084,644</u>	<u>825,502</u>	<u>-360,000</u>	<u>-916</u>	<u>0</u>	<u>2,070,172</u>
	<u>4,497,332</u>	<u>738,626</u>	<u>0</u>	<u>-360,000</u>	<u>0</u>	<u>0</u>	<u>4,875,958</u>

Pro Forma Adjustments

1. To record proceeds of \$738,626 from the exercise of 1,136,347 warrants at \$0.65 per warrant and to record the reclassification of the pro rata portion of the related derivative liability to equity.
2. To record the reclassification of the Dividend Warrant portion of the derivative liability to equity upon the amendment of all of the Dividend Warrants.
3. To recognize the October 2014 expenses.
4. To recognize the change in the fair value of the remaining unexercised Investor Warrants from September 30, 2014 to October 31, 2014.
5. To recognize share-based payments related to shares and stock options issued for services during October 2014.